17 completed, 7 unknown, 5 active not recruiting, 3 recruiting. 11 Phase 3, 9 Phase 2, 6 Phase 1, 4 Phase 4.
Follow Immunogenicity: new trials by email Literature Review of Immunogenicity trials Research Report on Immunogenicity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older Adults Standard dose influenza vaccine, MF59 adjuvanted influenza vaccine, High dose influenza vaccine - Influenza Vaccination, Older Adults (65 Years and Older) | Phase 4 | Recruiting | Korea University Guro Hospital | 180 | 2026-09-21 | 2026-09-24 |
| A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia quadrivalent HPV vaccine - Vaccine Effectiveness, HPV Vaccination | Phase 4 | Active not recruiting | International Agency for Research on Cancer | 1266 | 2026-06-01 | 2026-10-05 |
| Ex Vivo Immunogenicity Screening of Vaccine Candidate Antigen Combinations in Ethiopian Patients With Leishmaniasis Leishmaniasis, Cutaneous, Leishmaniasis | Recruiting | Institute of Tropical Medicine, Belgium | 90 | 2026-05-26 | 2026-08-24 | |
| Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema PRO-169 - Immunogenicity, Anti-drug Antibodies (ADAs) | Phase 1 | Not yet recruiting | Laboratorios Sophia S.A de C.V. | 60 | 2026-03-01 | 2026-03-13 |
| Influenza Vaccination Strategy for Patients With Hematologic Malignancy High-dose trivalent inactivated influenza vaccine (HD-IIV3), MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4), Standard-dose trivalent inactivated influenza vaccine (SD-IIV3) - Hematologic Neoplasms, Influenza | Phase 3 | Recruiting | Asan Medical Center | 120 | 2025-12-04 | 2026-09-01 |
| Real-world Immunogenicity of Anti-IL5/5a Antibody Asthma, Immunogenicity | Active not recruiting | Samsung Medical Center | 100 | 2025-08-19 | 2026-05-05 | |
| Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC MVA-BN standard regimen, MVA-BN standard regimen (Administered as PEP) - Neonate, Maternal Transmission | Phase 3 | Active not recruiting | Jean-Pierre Van geertruyden | 359 | 2025-06-23 | 2026-01-30 |
| Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC MVA-BN standard regimen, MVA-BN half-dose regimen - Mpox (Monkeypox), Vaccination | Phase 3 | Active not recruiting | Jean-Pierre Van geertruyden | 344 | 2025-05-29 | 2026-04-29 |
| A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2 Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2; - Immunogenicity, Safety | Phase 2 / Phase 3 | Unknown | Stemirna Therapeutics | 800 | 2023-06-20 | 2023-06-20 |
| Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia GP404141, Nplate - Drug Effect, Safety Issues | Phase 3 | Active not recruiting | Geropharm | 160 | 2023-04-04 | 2024-07-11 |
| mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs SW-BIC-213;SARS-Cov-2., Sinopharm (BIBP);SARS-Cov-2., Pfizer(BNT162b2);SARS-Cov-2. - Immunogenicity, Safety | Phase 3 | Unknown | Stemirna Therapeutics | 600 | 2022-10-19 | 2023-01-17 |
| New Generation mRNA Booster Vaccine Against Emerging VOCs SW-BIC-213, SARS-Cov-2 Vaccina(Vero Cell ) Inactivated - Immunogenicity, Efficacy | Phase 3 | Unknown | Stemirna Therapeutics | 2000 | 2022-10-01 | 2023-04-12 |
| Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, Placebo - COVID-19 Pandemic, Immunogenicity | Phase 2 | Completed | Sheba Medical Center | 179 | 2022-09-05 | 2024-02-21 |
| Immunogenicity of COVID-19 Vaccine on Heterologous Schedule Heterologous prime-boost schedule with AZD1222 and MVC-COV1901, Homologous prime-boost schedule with two doses of AZD1222 - Covid-19, Vaccine | Phase 2 | Completed | Chang Gung Memorial Hospital | 100 | 2021-09-15 | 2026-06-15 |
| Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Prospective Cohort Study SARS-CoV2 Infection, Covid19 | Unknown | Ottawa Hospital Research Institute | 150 | 2021-06-03 | 2024-03-07 | |
| Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies Immunogenicity, Hematological Malignancies | Unknown | Ospedale di Circolo - Fondazione Macchi | 300 | 2021-04-13 | 2021-09-13 | |
| Immunogenicity of the ChAdox1 n CoV-19 Vaccine With 12-dose Vial Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine - Covid19, Vaccine | Completed | Bangkok Metropolitan Administration Medical College and Vajira Hospital | 60 | 2021-04-01 | 2021-07-14 | |
| Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines This is observational study - Microbiome, Vaccine | Unknown | Korea University Guro Hospital | 53 | 2021-02-25 | 2021-12-09 | |
| COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS CoronaVac - Rheumatic Disease, HIV Infections | Phase 4 | Completed | University of Sao Paulo General Hospital | 2196 | 2021-02-09 | 2024-03-26 |
| Bioequivalence Clinical Trial of Recombinant Human Follicle-stimulating Hormone JZB30 Gonal F, jzb30 - Bioequivalence, Healthy Volunteers | Phase 1 | Completed | West China Second University Hospital | 48 | 2021-01-04 | 2025-01-16 |
Showing 20 of 33. Sign in to see all of them.
COVID-19 (7) · Hematologic Neoplasms (2) · Influenza, Human (2) · Mpox, Monkeypox (2) · Smallpox (2) · Acquired Immunodeficiency Syndrome (1) · Arthritis, Rheumatoid (1) · Asthma (1) · Cytomegalovirus Infections (1) · Dysentery, Bacillary (1) · HIV Infections (1) · Hearing Loss (1) · Leishmaniasis (1) · Leishmaniasis, Cutaneous (1) · Leishmaniasis, Visceral (1)
Infections (16) · Virus Diseases (13) · RNA Virus Infections (10) · Respiratory Tract Diseases (10) · Respiratory Tract Infections (9) · Lung Diseases (8) · Coronaviridae Infections (7) · Coronavirus Infections (7) · Nidovirales Infections (7) · Pneumonia (7) · Pneumonia, Viral (7) · DNA Virus Infections (3) · Animal Diseases (2) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (2) · Vi polysaccharide vaccine, typhoid (2) · 2019-nCoV Vaccine mRNA-1273 (1) · Adjuvants, Pharmaceutic (1) · ChAdOx1 nCoV-19 (1) · Hepatitis B Vaccines (1) · Influenza Vaccines (1) · MVA 85A (1) · MVC-COV1901 vaccine (1) · Vaccines (1) · follitropin alfa (1) · mRNA-1273.214 COVID-19 vaccine (1) · romiplostim (1) · sinovac COVID-19 vaccine (1) · smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (1)
PT Bio Farma (5) · Stemirna Therapeutics (3) · Jean-Pierre Van geertruyden (2) · Korea University Guro Hospital (2) · Asan Medical Center (1) · Bangkok Metropolitan Administration Medical College and Vajira Hospital (1) · Chang Gung Memorial Hospital (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Geropharm (1) · Institute of Tropical Medicine, Belgium (1) · Intas Pharmaceuticals, Ltd. (1) · International Agency for Research on Cancer (1) · Jiangsu Province Centers for Disease Control and Prevention (1) · Laboratorios Sophia S.A de C.V. (1) · Muhimbili University of Health and Allied Sciences (1)
Indonesia (5) · South Korea (4) · China (2) · Democratic Republic of the Congo (2) · Israel (2) · Laos (2) · Thailand (2) · Brazil (1) · Canada (1) · Ethiopia (1) · India (1) · Italy (1) · Mexico (1) · Mozambique (1) · Russia (1)
Mayfong Mayxay, doctor (3) · Adarsh K Garg, M.B.B.S (1) · Bernie E Medise, MD (1) · Bernie Endyarni, MD (1) · Bulat Bakirov, MD (1) · Dmitry Kirtbaya (1) · Dominicus Husada, Dr (1) · Eddy Fadliyana (1) · Elena Borisenkova (1) · Endalamaw Gadisa, PhD (1) · Eshetu Molla, PhD (1) · Feng-Ying C Lin, M.D. (1) · Francesco Passamonti, MD (1) · Galina Salogub (1)
PMID 16647790, PMID 23352749, PMID 30121146, PMID 31141635, PMID 32004693, PMID 32105293, PMID 32702298, PMID 33059607, PMID 33220855, PMID 33306989, PMID 34331051, PMID 34664616, PMID 34806342, PMID 34894235, PMID 34901885, PMID 34954325, PMID 35135832, PMID 35193873, PMID 35277389, PMID 35306594, PMID 35639644, PMID 35844042, PMID 36115850, PMID 36150668, PMID 36192386, PMID 36529052, PMID 36870351, PMID 37291679, PMID 38169790, PMID 38297337, PMID 38806352, PMID 40708707, PMID 41293254, PMID 42261247, PMID 42372625, PMID 42521300, PMID 42648772